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Background: A small percentage of children with Immune thrombocytopenic purpura (ITP) suffer from a
clinically signiﬁcant disease with severe thrombocytopenia that requires intervention. Treatment for
these children presents a challenge as there are few known therapies that offer long-term remission, and
all that are known have signiﬁcant side effects and toxicities.
Aim of the study: To evaluate the effects of a variety of treatment modalities on the clinical course, and
long treatment outcomes in children with chronic ITP.
Patients & methods: A study involved 60 children with chronic ITP who were referred to Hemato-
Oncology unit/Children's Welfare Teaching Hospital/Medical City/Baghdad. Treatment of patients
included steroid, Intravenous Immunoglobulins, Anti D immunoglobulin, 6-Mercaptopurine, Rituximab
and splenectomy. The Period of data collection and analysis was from May 2009 to May 2011.
Results: The most common presenting symptomwas skin bleeding, seen in 42 (70%) patients. Thirty-four
patients received one or more courses of steroids. Complete response was achieved in 7 (20.5%) patients
while there was no response in 12 (35.2%) patients, Intravenous immunoglobulin was used for 5 patients,
only one (16%) exhibited a good response. Anti D Immunoglobulin was used in six patients; only one
(8.3%) patient got good response. Twelve patients received 6-mercaptopurine, only one (8.3%) patient
had a partial response. Six patients received Rituximab; three (50%) had a partial response. Six patients
underwent splenectomy; response was noted in 5/6 (83.3%) patients. At the end of the study; complete
response was seen in 13 (22.4%) patients, partial in 19 (31.6%), no response in 28 (46.7%) patients.
Conclusions: Splenectomy is the most effective treatment modality when treating children with chronic
ITP whose symptoms are severe.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Immune thrombocytopenic purpura (ITP), is an acquired auto-
immune disorder deﬁned by isolated thrombocytopenia and the
exclusion of other causes of thrombocytopenia [1]. Acute ITP is the
most common cause of thrombocytopenia in children. Peakl-Jadiry).
atology Oncology Chapter of
apter of Indian Academy of Pediatr
enses/by-nc-nd/4.0/).occurrence is between 2 and 5 years of age. In most children with
acute ITP the disease is self-limited, with resolution in 80% of pa-
tients within 6e12 months from diagnosis [2]. Only a small subset
of childrenwith ITP have a clinically signiﬁcant disease with severe
thrombocytopenia and/or bleeding that requires intervention [3].
Persistent thrombocytopenia, will continue in 20e30% of chil-
drenwith acute ITP but nearly 25% of children with ITP will recover
within 12 months from the date of diagnosis [4]. Patients with
chronic refractory ITP are clinically heterogeneous. Some have
recurrent, severe bleeding, but most have intermittent, mild
bleeding. Some patients will have spontaneous, permanentics. Production and hosting by Elsevier B.V. This is an open access article under the
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less, most patients, will continue to have thrombocytopenia [5].2. Aim of the study
To evaluate the effects of various treatment modalities on the
clinical course, and long term outcome in childrenwith chronic ITP.3. Materials and methods
The study was involved 60 patients referred to the Hemato-
Oncology unit/Children's Welfare Teaching Hospital (CWTH)/
Medical City/Baghdad with chronic ITP, deﬁned as having platelets
count of <100  109/L for more than 6 months without identiﬁable
cause [6]. Data was collected from 1st of May 2009 until mid-May
2011. In addition to a detailed history and physical examination, the
diagnostic studies at CWTH included a full blood count, evaluation
of the stained peripheral blood smear, bone marrow aspiration,
biochemical proﬁle, routine tests of hemostasis, and antinuclear
antibody for collagen vascular diseases. Up until 2009 at CWTH;
steroid was the main– if not the only– option for treatment of ITP.
After that treatment, including other agents, was individualized
according to availability, the status of the disease and family
consent.Table 1
Response to different treatment modalities in chronic ITP.
Type of Drugs No. Response
Complete Partial None
1. Steroids
(one or more courses)
34 7 (20.6%) 15 (44.1%) 12 (35.3%)
2. IVIG 5 1 (20%) 0 4 (80%)
3. Anti D 6 1 (16.6%) 0 5 (83.3%)
4. Rituximab 6 0 3 (50%) 3 (50%)
5. 6 MP 12 0 1 (8.3%) 11 (91.6%)
6. Splenectomy 6 5 (83.3%) 0 1 (16.6%)
IVIG: Intravenous Immunoglobulin, 6 MP: 6 Mercaptopurine.3.1. Treatment options given to children with chronic ITP during the
study period include:
First line Treatment [6]:
1 Steroids
a. Prednisolone 1e2 mg/kg/day for 2e4 weeks
b. Methylprednisolone 500 mg/m2/day for 3days
c. Dexamethasone 4 mg/kg/day or 40mg/m2/day (maximum
40 mg) IV infusion for 3 days
d. Prednisolone 4 mg/kg/day for 4 days
e. Prednisolone 0.5 mg/kg every other day for several weeks up
to 6e12 months
2. Intravenous Immuno-Globulin (IVIG); 1e2 g/kg Intravenous
infusion over 4 h
3. Anti-D Immunoglobulin 50 mg/kg single dose IV infusion over
1 h or Intramuscular in the lateral aspect of the thighs.
Second line Treatment [6].
4. Mercaptopurine (6 MP); 50 mg/m2/day single time orally for
4e12 months according to response.
5. Rituximab 375 mg/m2/dose every week for 4 doses, If failed ﬁrst
line or second line treatment:
6 Splenectomy
The following measures were done before and after
splenectomy:
1. Pneumococcal vaccine given at least 2 weeks before surgery
2. Dexamethasone 40mg/m2/day Intravenously in two divided
doses over 3 days before surgery
3. Infusion of single donor platelets unit in the early morning
with checking of platelet's count 1 h after completing the
infusion, with another two units prepared standby.
4. After splenectomy; the patients kept on Benzathin penicillin
1.2 mega unit Intramuscular every 4 weeks.3.2. Response to therapy: Deﬁned as follows:
I. A complete response (CR) was deﬁned as return to normal
platelet count (greater than 150  109/L) during or after
therapy.
II. A partial remission (PR) was deﬁned as an increase in the
platelet count to greater than 50  109/L.
III. No response (NR) was deﬁned as no response to therapywith
continued platelet count below 50  109/L. [7].
4. Statistics
Calculations of means, medians and routine statistical measures
were performed by the mathematical component of the Microsoft
Excel spreadsheet program.
5. Results
Sixty patients were identiﬁed during the study period; they
were referred either from other hospitals, or those who were
already treated at CWTH. One patient was suffering from ITP since
1997 and the others were diagnosed after 2002. The median age at
time of diagnosis was 5 years, mean age was 5.5 years (range 8
monthse11.6 years). The peak age was 4 years. There were 25
(41.6%) boys and 35 (58.4) girls. The male-to-female ratio was 0.7:1.
There was a wide range of variation in the duration of symptoms
ranging from 1 day to 11 years. One patient was found to have low
platelet count during preoperative investigation for cochlear
implant due to congenital deafness.
5.1. Clinical presentations
The common presentation signs were skin bleeding alone in 41
(68.3%) patients followed by skin and mucous membrane in 17 pa-
tients (28.2%), one patient had hematoma after intramuscular injec-
tion of vaccine, and one patient had no bleeding or complaint. The
median platelet count at initial presentationwas 10 109/L, mean 16,
8 109/L (Range: zero to 69 109/L). Bone Marrow Aspirates at time
of diagnosis was done in 49 (81.6%) patients before commencing
steroids, the results were normal, 11 patients missed this evaluation
for unknown reasons. At re-evaluation at CWTH; 35 patients under-
went BMA as mandated by clinical assessment and only one patient
did not do the BMA neither at diagnosis nor at presentation to CWTH.
Coombs and Anti-nuclear antibodies were negative in all
patients at time of re-evaluation at CWTH.
5.2. Treatment of patients having chronic ITP
Oral steroids were generally the preferred/obligated agents in
patients treated in the study period. In patients whowere refractory
to steroids, those who became steroid-dependent to stay in remis-
sion, and those who relapsed, other options were tried (Table 1).
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I. Steroids therapy: Thirty-four patients received one or more
than one course of steroid; complete response was achieved
in 7 (20.5%) patients while no response in 12 (35.2%) pa-
tients, there was no response in 15 (44.1%) patients.
II. IVIG: Used for 5 patients, one (20%) patient showed complete
response, and 4 (80%) didn't show any response.
III. Anti D: Used for 6 patients who were Rhþve, the main
indication was recurrent generalized ecchymosis and mu-
cous membrane bleeding. Only one (16.6%) patient got
complete response, while5 (83.3%) showed no response.
Second line treatment:
I. Mercaptopurine (6MP): Used for 12 patients received 6 MP
at CWTH for a median period of 4.5 months, range (1e11
months). Only one (8.3%) patient showed partial response, he
didn't need any further treatment.
II. Rituximab: Used for 6 patients. Duration of assessment of
response was 8e9 months after initial dose of rituximab,
three (50%) patients got partial response and they were free
of symptom at time of last evaluation.
III. Splenectomy: Six patients underwent splenectomy after
failure of other modalities of treatment (ﬁrst or second line
treatment), the median age was 11.5 years (range
6.7e15.7years). Menorrhagia was the main indication for
splenectomy in the females while epistaxis was themain one
in males. The median duration of illness before doing sple-
nectomy was 3 years (range 1.7e13.3 years). Immediate
response was noted in 5/6 patients with increment of
platelet's count to a median of 325  109/L (range
156e625  109/L) within two days from splenectomy with
no surgical complication during or after splenectomy.6. Overall outcome
The median duration of chronic illness in those patients was 21
months (range 2e164 months) at time of last evaluation. Follow up
period: median 20.5 months, (range 1e164 months), 10 patients
were lost to follow up in 2009 and 2010, while the rest continued
follow up till the end of the study period. Final response: Complete
responsewas seen in 13 (22.4%), partial in 19 (31.6%), no response in
28 (46.7%) (Table 2).7. Discussion
Immune thrombocytopenic purpura is a common hemorrhagic
disease in childhood, with a heterogenous presentation and
response to therapy during childhood. It is likely that all pediatri-
cians will encounter childrenwith ITP at some time in their practice
[7]. Patients with acute ITP are not usually followed by the pediatric
hematologist at CWTH. The benign nature of the disease makes it
difﬁcult for families to accept the idea of admission to the oncologyTable 2
Overall outcomes.
Response No. % Clinical status
CR 13 22.4 No bleeding
PR 19 31.6 Ecchymosis in 1, no
bleeding in 16, unknown in 2
NR 28 46.7 No bleeding in 6, ecchymosis
in 12, epistaxis in 4,
menorrhagia in 1, unknown in 5unit. It was not possible to know the exact number and thus the
percentage of children with chronic ITP for the purpose of this
study as some patients were referred to CWTH while in a chronic
phase. While the number of children involved in this study is fairly
small, it might nonetheless be helpful in highlighting some
distinctive behaviors and management problems with this partic-
ular group of patients. The median age of patients at time of
diagnosis was 5 years (mean 5.5 years), the peak age was 4 years. A
large-scale study done in China by Zhao H. involving 472 consec-
utive Chinese children with chronic ITP (age 1e14 years) showed
the same peak age of 4 years [8]. There are other studies of patients
with chronic ITP that showa highermedian age at time of diagnosis
[7,9]. The difference in the median agemight be attributed to wider
age range in other studies. In the current study; there were 25 boys
and 35 girls. The male-to-female ratio was 0.7:1. There is similar,
slight female predominance reported in other studies [7,9e11].
There is an extreme variable in the duration of symptoms from the
time of diagnosis of ITP in our study ranging from 1 day to 11 years.
The study byWong MS reported a similar range (0e520) weeks [9].
The symptoms might endure over long periods due to a delay in
diagnosis. This could be attributed to the somewhat insigniﬁcant
symptoms presenting in the patient and the fact that the family is
unaware that the child is sick. There was an absence of intracranial
bleeding in this study group. This might be explained by a bias in
referral as most of patients came from other hospitals and were in
relatively stable condition. Or it might be simply be a reﬂection of
the benign course of the chronic ITP as reported in the study by
Glanz J which showed cutaneous bleeding in 52/60 (88%) patients,
mucosal in 9/60 (23%) patients and no patient got internal bleeding
[10]. while Kühne T study showedmore aggressive presentations in
Asian and European groups of children [12].7.1. Response during chronic phase
In the current study, the CR to steroids was 20.6% which is lower
than reported in other studies [8,9], this might reﬂect a refractory
behavior in our group. The response to single course of IVIG in our
study was similar to the steroid response, Wong [9] shows a lower
response of 14.3%. the number of patients in both studies is small
for evaluation. Aronis [13] showed a better response 10/26 (38.5%)
after variable courses of IVIG (range 3-7courses).
Our results with anti D were not satisfactory, other studies
showed more optimistic responses [14] but they were using more
than one course of anti-D. In our study; the response to 6 MP was
not satisfactory after having a variable periods of treatment in
response to side effects or when the family refused extended/
continued us of the drug. There are few published studies on the
use of 6 MP in children with much better results (80e85%) than
ours [15,16]. In our study the best result was with splenectomy
where the response rate was 83.3%. the numbers are small but
signiﬁcant in light of the many technical and logistical obstacles we
faced. Other studies present similar results with a response rate of
66.7e100% [8,11,17e19]. Our study showed a partial response to
rituximab in 50% patients, the rest were non responders. There are
few studies published showing the effect of rituximab in children
with chronic ITP; Bennett CM et al. [20] showed a response in 7/30
(23%) children with chronic ITP.7.2. Overall outcome
There were 28 (46.7%) non-responder patients; six (10%) pa-
tients remained asymptomatic while 22 (80%) had variable
bleeding. None of our patients had CNS bleeding or died from any
cause in addition to bleeding during the period of follow.
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40e55% still having signiﬁcant thrombocytopenia during the
period of the study [7,19]. on the contrary some studies showed
better responses (62.6%) with signiﬁcant number of them under-
went splenectomy [11].
8. Conclusions
1. In children with chronic ITP with severe symptoms and signif-
icant thrombocytopenia, splenectomy is the most effective
treatment with minimal immediate complication; still late
complications require a longer follow up period.
2. About half of children with chronic ITP in this study achieved
remission.
3. Rituximab therapy is beneﬁcial for some children with severe
chronic ITP who are refractory to standard agents.Conﬂict of interest
The authors declare no conﬂict of interest.
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